ArticleThe lancet. Gastroenterology & hepatology2019

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

Maeve A Lowery et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.